

# Help Repair and Soothe Your Skin from the Inside Out

EBGLYSS was studied in 3 clinical trials with more than 1,000 adults and children (ages 12+) with moderate-to-severe eczema not well controlled with topical prescription treatments. See the before and after results for clinical trial patients treated with EBGLYSS. Individual results may vary.

## Select Important Safety Information

**Do not use EBGLYSS** if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

### Patient A | 24 years old<sup>1</sup>



### Patient B | 53 years old<sup>1</sup>



### Patient C | 18 years old<sup>1</sup>



### Patient D | 18 years old<sup>2</sup>



**White background added for a consistent presentation across treatment time periods. Close-up images show target lesions. Patients taking EBGLYSS also experienced itch relief.** In an average of two studies (ADVocate 1 and 2), 38 percent of people who took EBGLYSS achieved clear or almost-clear skin (IGA 0,1) at 16 weeks (versus 12 percent with placebo). On average, 43 percent of people who took EBGLYSS felt itch relief at 16 weeks (compared to 12 percent who took placebo).

#### Investigator's Global Assessment (IGA) Score

A five-point scale that provides a global clinical assessment of severity of disease ranging from 0 to 4, where 0 indicates clear, 1 is almost clear, 2 is mild, 3 is moderate, and 4 indicates severe eczema.

Patients A through D in the clinical trials received an initial dose of EBGLYSS 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16. The recommended dosage of EBGLYSS is an initial dose of 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dose is 250 mg every four weeks.

The endpoint measured for patients A through D was an IGA score of clear (0) or almost clear (1) skin with a reduction of at least two points from baseline at 16 weeks.

## INDICATION AND SAFETY SUMMARY

EBGLYSS™ (EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids.

It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).

**Warnings – Do not use EBGLYSS** if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

### Before using

**Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:**

- Have a parasitic (helminth) infection.
- Are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with EBGLYSS.
- Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy.
- Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

### Possible side effects

**EBGLYSS can cause serious side effects, including:**

- **Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe.** Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms:
  - breathing problems or wheezing
  - swelling of the face, lips, mouth, tongue or throat
  - hives
  - itching
  - fainting, dizziness, feeling lightheaded
  - skin rash
  - cramps in your stomach area (abdomen)
- **Eye problems.** Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision.

### The most common side effects of EBGLYSS include:

- eye and eyelid inflammation, including redness, swelling, and itching
- injection site reactions
- shingles (herpes zoster)

**These are not all of the possible side effects of EBGLYSS.** Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

### How to take

- **See the detailed “Instructions for Use” that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes.**

- Use EBGLYSS exactly as prescribed by your healthcare provider
- EBGLYSS is given as an injection under the skin (subcutaneous injection).
- If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver.
- If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time.

### Learn more

EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call **1-800-545-5979** or go to [ebglyss.lilly.com](http://ebglyss.lilly.com).

This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you.

LK CON BS AD APP

References  
1. Data on File, Lilly USA, LLC, DOF-LK-US-0037. 2. Data on File, Lilly USA, LLC, DOF-LK-US-0039